Search NLS News

NLS asked Chiara Facciotto, Innovation Ecosystem Lead at Meilahti Medical Campus, University of Helsinki, and Anu Meerwaldt, Development Manager at SPARK Finland, about the upcoming Y Science event on November 20 and about the start-up climate in Helsinki.

The 30th edition of BIO-Europe was held at Stockholmsmässan in Älvsjö on November 4-6, and Nordic Life Science was there to cover, report and bring you some of the highlights.

In the summer of 2025, Takeda will move in with about a hundred employees on approx. 830 square meters on floor 2 in Forskaren.

Medivir has announced a clinical trial collaboration and supply agreement with Eisai to evaluate fostrox in combination with lenvatinib mesylate in a randomized, phase 2b study in second-line advanced liver cancer patients.

NEOGAP Therapeutics has entered a strategic collaboration with NorthX Biologics to advance manufacturing strategies for NEOGAP’s personalized cancer cell therapy.

Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.

You are arranging a Nordic tour, beginning at BIO-Europe in Stockholm on November 4-6, for different actors within life science manufacturing to showcase our region’s strengths within the field.

Downsizing a company is one of the most difficult decisions a chief executive can make, after which comes the equally painful decision of when to do it.

Åsa Uppströmer joins PharmaRelations from a position as branch manager for the Stockholm area in the large Frensch IT consulting group, Sogeti, part of the French listed giant Cap Gemini.

The Nordics is a small region and access to capital is limited, so many biotech companies do not have the financial strength to develop more than one product from their platform. Seeking licensing partners for the later stages of clinical development and subsequent commercialization is therefore a strategy that many SMEs adopt, and need to adopt.